GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Minapharm Pharmaceuticals (CAI:MIPH) » Definitions » EBIT

Minapharm Pharmaceuticals (CAI:MIPH) EBIT : E£156 Mil (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Minapharm Pharmaceuticals EBIT?

Minapharm Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was E£185 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was E£156 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Minapharm Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2024 was 3.53%. Minapharm Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 6.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 2.03%.

Minapharm Pharmaceuticals EBIT Historical Data

The historical data trend for Minapharm Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minapharm Pharmaceuticals EBIT Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec22 Dec23
EBIT
942.51 287.49

Minapharm Pharmaceuticals Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
EBIT - 315.91 -28.42 184.64

Competitive Comparison of Minapharm Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minapharm Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's EV-to-EBIT falls into.


;
;

Minapharm Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was E£156 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals  (CAI:MIPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Minapharm Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=246.794 * ( 1 - -19.26% )/( (7283.324 + 9414.573)/ 2 )
=294.3265244/8348.9485
=3.53 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8703.565 - 908.977 - ( 1917.841 - max(0, 3531.005 - 4042.269+1917.841))
=7283.324

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11269.764 - 1196.922 - ( 3263.61 - max(0, 4783.61 - 5441.879+3263.61))
=9414.573

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Minapharm Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=369.272/( ( (4251.47 + max(626.272, 0)) + (5199.758 + max(506.625, 0)) )/ 2 )
=369.272/( ( 4877.742 + 5706.383 )/ 2 )
=369.272/5292.0625
=6.98 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(517.029 + 1054.99 + 295.734) - (908.977 + 0 + 332.504)
=626.272

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(395.708 + 1267.872 + 288.126) - (1196.922 + 0 + 248.159)
=506.625

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=156.212/7705.896
=2.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Minapharm Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Minapharm Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Minapharm Pharmaceuticals (CAI:MIPH) » Definitions » EBIT
Comparable Companies
CAI:RMDA CAI:PHAR ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692 SZSE:000538 BOM:500087 ITCI VTRS TSE:4507 NBIX NSE:TORNTPHARM SHSE:688506
Traded in Other Exchanges
N/A
Address
El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Website
https://www.minapharm.com
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.

Minapharm Pharmaceuticals Headlines

No Headlines